HC Wainwright reissued their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note published on Tuesday morning. HC Wainwright currently has a $75.00 price objective on the biotechnology company’s stock.

A number of other research analysts also recently commented on SRPT. Leerink Swann reiterated an outperform rating and set a $66.00 target price on shares of Sarepta Therapeutics in a research report on Saturday, September 30th. Instinet reiterated a buy rating and set a $84.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. JPMorgan Chase & Co. reiterated a hold rating on shares of Sarepta Therapeutics in a research report on Monday, September 25th. BidaskClub downgraded Sarepta Therapeutics from a buy rating to a hold rating in a research report on Saturday, January 6th. Finally, Janney Montgomery Scott assumed coverage on Sarepta Therapeutics in a research report on Wednesday, January 3rd. They set a buy rating and a $75.00 target price for the company. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $63.88.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down $0.15 on Tuesday, reaching $58.99. 1,633,700 shares of the company’s stock were exchanged, compared to its average volume of 2,409,650. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44. Sarepta Therapeutics has a twelve month low of $26.26 and a twelve month high of $60.22. The stock has a market cap of $3,980.00, a price-to-earnings ratio of -28.92 and a beta of 1.37.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. The firm had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same period in the prior year, the company earned ($0.95) EPS. equities research analysts expect that Sarepta Therapeutics will post -3.07 EPS for the current year.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total value of $372,618.63. Following the sale, the director now owns 13,333 shares in the company, valued at $745,181.37. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Douglas S. Ingram bought 38,138 shares of Sarepta Therapeutics stock in a transaction on Wednesday, November 8th. The stock was acquired at an average price of $52.44 per share, for a total transaction of $1,999,956.72. Following the purchase, the chief executive officer now owns 420,196 shares of the company’s stock, valued at $22,035,078.24. The disclosure for this purchase can be found here. 9.60% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Neuberger Berman Group LLC purchased a new stake in Sarepta Therapeutics in the third quarter worth $1,134,000. California Public Employees Retirement System increased its stake in Sarepta Therapeutics by 1.2% in the third quarter. California Public Employees Retirement System now owns 142,900 shares of the biotechnology company’s stock worth $6,482,000 after purchasing an additional 1,700 shares during the period. Janney Montgomery Scott LLC purchased a new stake in Sarepta Therapeutics in the third quarter worth $474,000. Ladenburg Thalmann Financial Services Inc. increased its stake in Sarepta Therapeutics by 140.9% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 2,493 shares during the period. Finally, Highbridge Capital Management LLC purchased a new stake in Sarepta Therapeutics in the third quarter worth $922,000. Institutional investors and hedge funds own 82.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/sarepta-therapeutics-srpt-buy-rating-reaffirmed-at-hc-wainwright/1804594.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.